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ABSTRACT 
A simple, specific, accurate and precise new high performance liquid chromatographic 
method was developed for the estimation of irbesartan in bulk and its developed dosage form. 
The mobile phase containing acetonitrile: Phosphate buffer pH 3.5 in proportion of 50:50 v/v 
was employed with flow rate of1.0 ml/min and eluting medium was monitored at 240 nm. 
The method was validated for linearity, accuracy, precision, limit of detection, limit of 
quantification and robustness for irbesartan. A linear response was observed in the range of 5-
40µg/ml. Linear regression of absorbance on concentration gave equation y = 101.9x + 195.3 
with a regression co-efficient r2=0.993. The method was validated for different parameters as 
per the ICH guidelines. The degradation studies were carried out by using the developed 
method. Thus the method was found to be useful for the determination of irbesartan in bulk as 
well as for dosage forms. 
 
Introduction 
 
Irbesartan is an angiotensin II, the principal pressor agent 
of the renin-angiotensin system, is responsible for effects 
such as vasoconstriction, stimulation of synthesis and 
release of aldosterone, cardiac stimulation, and renal 
reabsorption of sodium. The chemically irbesartan is 2-
butyl-3-({4-[2-(2H-1,2,3,4-tetrazol-5yl) phenyl]phenyl} 
methyl)-1,3- diazaspiro[4.4]non-1-en-4-one with 
molecular weight of 428 and practically insoluble in 
water[1]. 
 
 
Structure of irbesartan 
 
It is mandatory requirement from regulatory authorities 
to show the proper qualification of its degradation 
pathways and characterization of known degraded 
product that are present. Degradation can arise during the 
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shelf life/ storage as of the drug substances and their 
acceptance based on studies or known safety data need to 
be studied. In the investigation an ideal stability 
indicating chromatographicmethod which estimates the 
drug and able to resolve the drug from its degradation 
products. Hence an attempt has been made to develop an 
accurate, rapid and reproducible method for the 
determination of irbesartanin presence of its degradation 
products for its content analysis in pharmaceutical 
dosage form as per ICH guidelines [2,3]. The objective 
of the study is to develop an accurate, rapid and 
reproducible method for the determination of irbesartan 
in presence of its degradation products for its content 
analysis in pharmaceutical dosage form as per ICH 
guidelines. 
 
Materials and Methods 
 
Instrument:  The liquid chromatographic system consist 
of Cyberlab MAO1527, USA withbinary double 
reciprocating high pressure gradient mixer withUV/VIS 
detector.Analysiswasperformedusingcolumn C-18 (250 
mm length x 4.6 mm internal    diameter and 5 µm 
particle size.  
 
Reagents and materials 
 
Irbesartan was obtained as gift samples from Que 
Pharmaceutical Pvt. Ltd, Wadhvan, Gujrat. HPLC grades 
water, HPLC grades Acetonitrile were purchased from 
Merck, Research lab, Molychem,India. All chemicals 
were of analytical grade. 
 
Preparation of stock solution  
 
Irbesartan (50 mg) was accurately weighed and 
transferred to a volumetric flask of 25 ml capacity. 
Volume was made upto 25 ml with HPLC grade 
methanol. Ten ml of this solution was diluted to 100 ml 
with mobile phase containing acetonitrile: phosphate 
buffer pH 3.5 (50:50 v/v) to obtain concentration of 200 
µg/ml. Further dilutions  
 
Chromatographic Conditions 
 
The mobile phase consisting were filtered through 
membrane filter, degassed and pumped through solvent 
reservoir in 50:50 proportion into the column with flow 
rate of 1.0 ml/min and wavelength of 240 nm set for the 
determination of irbesartan. The volume of injection loop 
was 20µl prior to injection of the drug solution the 
column was equilibrated with mobile phase for 30 min. 
The column and the HPLC system were kept in 22°C 
with pressure of 8 psi. 
 
Preparation of calibration curve  
 
The standard solutions of 5 to 40 µg/ml of irbesartan 
were prepared form the stock solution. These solutions 
were injected into HPLC column of chromatographic 
system. The plot of AUC versus concentration of 
irbesartan and coefficient of regression was determined 
[4, 5, 6].  
 
Method validation 
 
The developed method was validated for linearity, 
precision, robustness, limit of detection and limit of 
quantification [7,8]. 
 
Linearity 
 
It is a measure of how well a calibration plot of response 
vs concentration approximates a straight line. A series of 
concentrations were injected and the linearity range was 
established. The experiments were repeated in triplicate.  
 
Precision 
 
Solution with 20 µg/ml concentration were injected 
repeatedly (n=3) by averaging the peak areas and 
determination of SD and RSD of all injections. 
Intermediate precision (intra and iner day) was performed 
by measuring absorbance of standard solution at three 
different time during single day and on three consecutive 
days respectively.  
 
Robustness 
 
To validate the robustness of the developed method, 
small change in system parameters was carried out and 
its effect on resultant retention time (tR) was determined. 
Variations in mobile phase composition (± 2%) and flow 
rate (+ 1.5 and -0.5ml/min) has been done. The results 
were compared with the earlier results. 
 
Limit of detection (LOD) and Limit of quantification 
(LOQ) 
 
LOD is defined as the lowest concentration of an 
analytein a sample that can be estimated. It was 
determined by first examining the noise of the instrument 
by injecting the mobile phase in triplicates and finding 
values with the highest and lowest peak areas at a range 
covering the retention time of the drug. The difference in 
the areas gave the noise of the instrument. Peak areas 
having three times the noise give an estimate of the LOD. 
The LOD is calculated by using the following formula, 
3 σ 
LOD=  ---------- 
S 
Where, σ- standard deviation 
 S- slope of the calibration curve 
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LOQ is the smallest concentration of analyte, which 
gives a response that can be accurately quantified. Noise 
of the instrument was determined as given above and the 
peak area having ten times the value of noise give an 
estimate of LOQ. 
The LOQ is calculated by using the following formula, 
10 σ 
LOQ=  ---------- 
S 
Where, σ- standard deviation 
             S- Slope of the calibration curve 
 
Forced Degradation Study of irbesartan 
 
Forced degradation study of irbesartan in bulk was 
carried out under the conditions of acid hydrolysis, 
alkaline hydrolysis, oxidation study.  
 
Acid hydrolysis 
 
To 10 mlof stock solution (200 µg/ml), 10 ml of 0.1 M 
HCl was added to obtain the working standard of drug. 
The solution was refluxed for 2 h at 70°C, the solution 
was neutralized. One ml of the resultant solution was 
diluted with mobile phase upto 10 ml. A 20 µl of 
resulting solution was injected into HPLC, under 
optimized chromatographic conditions. 
 
Alkaline degradation 
 
To 10 ml of stock solution (200 µg/ml), 10 ml of each 0.1 
M NaOH was added to obtain the working standard of 
drug. The solution was refluxed for 2 hat 70°C, the 
solution was neutralized. One ml of the resultant solution 
was diluted with mobile phase upto 10 ml. A 20 µl of 
resulting solution was injected into HPLC, under 
optimized chromatographic conditions. 
 
Oxidation studies 
 
Hydrogen Peroxide (3 %) solution for oxidation studies 
was prepared in water. To 10 ml of stock solution (200 
µg/ml), Ten ml of 3 % H2O2 Solution was added. The 
solution was refluxed for 2 hat 70°C.One ml of the 
resultant solution was diluted with mobile phase upto 10 
ml. A 20 µl of resulting solutions was injected into 
HPLC, under optimized chromatographic conditions. 
 
 
 
Formulation of dosage form 
 
The inclusion complex of irbesartan: β-cyclodextrin (β-
CD) with soluplus by freeze drying was prepared as per 
the method described by Kulkarni N. S. et. al. [9]. The 
freeze dried inclusion complex equivalent to 75 mg of 
inclusion complex were passed through the sieve no 66 # 
respectively and weighed. The aerosil, lactose and talc 
were added to the inclusion complex 80 mg, 30 mg and 5 
mg respectively. The powders were filled into hard 
gelatin capsule (size 3) shell and evaluated for drug 
content by developed HPLC method. 
 
Stability Study 
 
The prepared formulation was kept in the stability 
chamber maintained at 40°C and 75 % RH for period of 
six months. The samples were withdrawn at 0, 1, 2, 3 and 
6 months and evaluated for drug content by using 
developed HPLC method. 
 
Drug content during stability 
 
Ten capsules were accurately weighed. Powder 
equivalent to 75 mg of drug was placed in a 100 ml 
volumetric flask, methanol was added and sonicated. The 
suspension was sonicated in a sonicator water bath for 15 
min. These were then allowed to stand and volume was 
made with HPLC grade methanol. The suspension was 
filtered through whatman filter paper (0.22 µ) and 10 ml 
of the filtrate was transferred to volumetric flask of 100 
ml. Volume was made up with mobile phase and solution 
was analyzed by HPLC. 
 
Result and Discussion 
 
Optimization of mobile phase was performed based on 
symmetric peak and peak area obtained. Different 
proportion of phase acetonitrile with phosphate buffer pH 
3.5 were tried but the well resolved and symmetrical 
peak was obtained in proportion of 50:50 v/v ratio. The 
retention time (tR) for irbesartan was found to be 1.50 
min (Figure 1). The number of theoretical plate was 
found to be 11218, which suggests efficient performance 
of the column. Standard curve for irbesartan was 
obtained by plotting AUC verses concentration in µg/ml. 
Linear relationship between AUC and concentration was 
found in the range of 5 – 40µg/ml (y = 101.9x + 195.3, r 
= 0.993) where x – concentration of irbesartan and y – 
respective peak area.   
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Figure 1: HPLC chromatogram of irbesartan in mobile phase
 
Method validation  
Linearity 
 
The linear relationship between AUC and concentration 
was found in the range of 5-40 µg/ml (y= 101.9 x+ 195.3, 
r= 0.993). It can be concluded that the method was found 
to be linear.  
 
 
Table 1: Precision data of 
Conc in  
µg/ml 
AUC 
20 (Intra day) 2103 
20 after 1 day 2110 
20 after 2 day 2112 
 
Robustness 
 
Influence of small change in chromatographic conditions 
such as change in flow rate, change in percentage of 
acetonitrile in mobile phase and column temperature 
 
Table 2:
Factor 
Flow rate 
Change in Acetonitrile 
 
Limit of detection (LOD) and Limit of quantification 
(LOQ) 
 
The LOD of irbesartan was found 0.05 µg/ml and LOQ 
of irbesartan was found 0.16µg/ml. 
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Precision 
 
The intra and inter day study for the method was done 
and low value of RSD for irbesartan revealed that the 
proposed method is precise (table 1).
irbesartan (Intraday and Inter day)
 
AUC AUC Average 
2105 2101 2103 
2105 2108 2107 2.51
2107 2108 2109 2.64
were studied to determine robustness of the method. The 
results showed that there is no signifi
retention time (% RSD < 2%) of irbesartan as 
summarized in table  2. 
 Variation in parameter and its effect on retention time
 
Level Retention Time (t
0.5 ml/mim 1.53 
1.5 ml/min 1.45 
 
48 % 1.48 
52 % 1.51 
Forced Degradation of Irbesartan
 
The results of forced degradation studies are given in 
table 3 and figure 2 to 4. Significant degradation was 
observed under acidic and basic conditional and 
additional peaks of degradation products were observed. 
No additional peak was observed in case of oxi
studies but significant change in retention time has been 
observed. 
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SD  RSD 
2.0  0.0009 
  0.001 
  0.001 
cant change in 
 
R) 
 
dation 
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Figure 2: HPLC chromatogram of irbesartan degradation product in 0.1 HCl
Figure 2: HPLC chromatogram of irbesartan degradation product in 0.1 NaOH
Figure 3: HPLC chromatogram of irbesartan degradation product in 3 % H
Table 3: % degradation of irbesartan in acidic, basic and hydrolysis conditions
Stress 
Degradation 
Amount of irbesartan 
Degraded 
0.1 M HCL 67.26 
0.1 M NaOH 67.13 
3 % H2O2 77.94 
 
 
Stability study of formulation 
 
No significant change was observed in capsules 
properties with respect to appearance, drug content 
studies at condition of 40°C/75% RH for a period of six 
months. Absence of co eluting peak during the stability 
analysis along with the irbesartan peak indic
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Amount of irbesartan 
Recovered 
Retention time of degraded 
product
32.73 1.75, 2.17, 6.10
32.86 1.75, 6.60
22.05 2.09 
ates that the 
developed HPLC method is specific for irbesartan and it 
is concluded that irbesartan does not undergo degradation 
at accelerated stability conditions when formulated as 
capsule dosage form containing
cyclodextrin with soluplus
guidelines, the formulation was found to be stable.
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2O2 
 
 
 
 
 irbesartan: β-
. Hence according to ICH 
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Table 4: Drug content of Freeze dried irbesartan: β-CD: soluplus Capsule during stability 
 
Sampling 
interval 
Drug content 
40ᵒC 75% RH 
0 day 96.25± 0.34 
1months 97.29±0.21. 
2  months 99.03± 0.43 
3  months 96.29± 0.34 
6 months 98.23 ± 0.65 
 
Conclusion 
 
Proposed HPLC method describes a new quantitation method 
for irbesartan. The method was found to be simple, sensitive 
and accurate. The proposed method can be used for routine 
analysis of irbesartan in bulk and for its developed formulation 
as well as accelerated testing in bulk and pharmaceutical 
dosage forms. 
Conflict of interest: We declare that we have no conflict 
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